4538 — Fuso Pharmaceutical Industries Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapNeutral

Annual income statement for Fuso Pharmaceutical Industries, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	46,901	49,251	49,632	51,015	55,407
Cost of Revenue
Gross Profit	12,800	14,109	13,397	13,740	13,839
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	45,953	46,911	47,793	48,819	53,583
Operating Profit	948	2,340	1,839	2,196	1,824
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,042	2,345	1,911	2,205	1,767
Provision for Income Taxes
Net Income After Taxes	707	1,608	1,484	1,606	1,378
Net Income Before Extraordinary Items
Net Income	707	1,608	1,484	1,606	1,378
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	707	1,607	1,483	1,605	1,377
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	82.4	177	177	184	173
Dividends per Share